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CIRI-CIRI KLINIKAL, PENJENISAN GEN DAN KAEDAH 
PENGESANAN MOLEKULAR BAGI Burkholderia pseudomallei 
 
ABSTRAK 
Burkholderia pseudomallei ialah bakteria saprofitik Gram negatif yang boleh 
menjangkiti manusia melalui saluran pernafasan, pengingesan atau melalui kulit, dan 
meyebabkan penyakit melioidosis. Patofisiologi dan gejala klinikal penyakit 
melioidosis bergantung kepada jumlah bakteria, cara jangkitan diperolehi serta 
faktor-faktor risiko yang ada pada manusia. Terdapat berbagai kaedah makmal yang 
melibatkan B. pseudomallei termasuklah ujian pengesanan, kajian epidemiologi 
molekular dan kajian patogenisiti yang menggunakan kaedah konvensional, 
immunologi dan molekular. 
 
Kajian dalam tesis ini mendalami ciri-ciri klinikal dan faktor-faktor risiko penyakit 
melioidosis. Penentuan genotip dengan menggunakan kaedah multilocus sequence 
typing (MLST) telah dilakukan ke atas isolat klinikal B. pseudomallei untuk 
mengkaji kepelbagaian genetik serta perhubungan antara genotip dengan ciri-ciri 
klinikal, prognosis dan kesudahan penyakit melioidosis. Bagi mempertingkatkan 
kebolehkesanan B. pseudomallei, satu asai berasaskan tindak balas rantai polimerase 
(PCR) yang menyasarkan gen sctq dari kluster TTS1telah dibangunkan. 
 
Dalam kajian yang melibatkan 158 kes, gejala klinikal utama yang diperolehi adalah 
infeksi paru-paru (n=65, 41.1%), infeksi kulit (n=44, 27.8%), artritis 
septik/osteomielitis (n=20, 12.7%) dan infeksi hati (n=19, 12%). Melioidosis 
bakteremik telah didapati dalam sebahagian besar pesakit (n=121, 76.6%). Seramai 
124 pesakit (78.5%) mendapat melioidosis setempat (lokal), 45 pesakit (28.5%) 
xix 
 
mendapat melioidosis multifokal, manakala seramai 34 pesakit (21.5%) menghidap 
melioidosis tanpa punca yang nyata. Abses organ dalaman serta fokus sekunder 
dalam paru-paru dan tisu badan juga banyak didapati dalam kajian ini. Enam puluh 
tujuh pesakit (41%) telah mendapat penyakit pada musim monsun lembap 
(tengkujuh). Kematian disebabkan melioidosis telah melibatkan seramai 52 pesakit 
(32.9%), manakala infeksi berulang melibatkan 4 pesakit (2.5%). Kajian ini juga 
menjumpai 12 kes kematian yang melibatkan pesakit yang tidak mendapat rawatan 
fasa akut. Faktor risiko bagi penyakit melioidosis dijumpai dalam sebahagian besar 
pesakit (n=133, 84.2%). Ini termasuk diabetes (74.7%), gangguan sistem imun badan 
(9.5%), kanser (4.4%) dan penyakit buah pinggang kronik (11.4%). Dalam analisis 
multivariat, penelah bebas bagi kes mortaliti melioidosis adalah kewujudan 
sekurang-kurangnya satu faktor morbiditi (OR 3.0; 95% CI 1.1–8.4), kejutan sepsis 
(OR 16.5; 95% CI 6.1–44.9) dan umur >40 tahun (OR 6.47; 95% CI 1.7–23.8). 
 
Penjenisan gen menggunakan kaedah MLST, yang dilakukan ke atas 83 isolat B. 
pseudomallei telah menjumpai 32 genotip yang berbeza, termasuk 13 genotip yang 
baharu (novel), iaitu: ST1317, ST1318, ST1319, ST1320, ST1321, ST1322, ST1323, 
ST1324, ST1325, ST1326, ST1327, ST1358 dan ST1359. Kesemua genotip yang 
ditemui dalam kajian ini dihantar dan disimpan dalam pangkalan data MLST. Dalam 
kalangan 83 isolat yang diuji, kekerapan sesuatu genotip adalah dalam lingkungan 1-
12 kali dan genotip yang paling lazim atau pradominan adalah ST54, ST371 dan 
ST289. Genotip-genotip sedia ada (non-novel) yang ditemui dalam kajian ini tidak 
didapati secara eksklusif di Malaysia sahaja, tetapi juga didapati di negara-negara 
sekitar yang lain dengan kekerapan yang berbeza. Walau bagaimanapun terdapat 
xx 
 
genotip yang julung kali dijumpai di Malaysia iaitu ST371, ST164, ST47, ST306, 
ST55, ST376, ST402, ST507, ST368, ST369, ST10 dan ST168. 
 
Menurut analisis data MLST, pokok filogenetik yang terhasil menunjukkan lebih 
daripada separuh genotip terkumpul dalam gugusan yang sama, termasuklah genotip-
genotip dari Malaysia, Thailand, Singapore, Cambodia, Vietnam, Laos dan China. 
Genotip-genotip yang baharu juga terkumpul dalam gugusan yang sama dalam 
pokok filogenetik. Satu-satunya genotip unik yang bersendirian dalam pokok 
filogenetik ialah ST1326, yang juga genotip baharu. Kajian ini telah memperluaskan 
pangkalan data yang sedia ada bagi genetik populasi B. pseudomallei di Malaysia 
dengan menambahkan cabang-cabang genotip dan mewujudkan kluster atau gugusan 
baharu berikutan pengembangan klonal yang bercambah dari ST84. 
 
Secara evolusi, tiada bukti perkaitan antara genotip B. pseudomallei dengan gejala 
klinikal melioidosis. Penumpuan mana-mana genotip terhadap sesuatu kesudahan 
klinikal juga tidak didapati dalam kajian ini. Kelainan dari segi kevirulenan atau 
tropisme juga tidak ditemui. Sepsis yang teruk (n=11) dilihat berhubung kait dengan 
tujuh genotip yang berbeza, manakala kejutan sepsis (n=29) dan abses (n=30) 
berpunca dari 17-18 genotip yang berlainan. Sepsis, pneumonia, ensefalopati serta 
infeksi organ lain dan kesudahan penyakit adalah berhubung kait dengan beberapa 
genotip yang berbeza-beza.  Analisis bagi menentukan perkaitan antara kluster 
genotip dengan kesudahan klinikal juga tidak menunjukkan perkaitan yang signifikan 
secara statistik. 
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Asai PCR yang dibangunkan telah dioptimisasikan bagi mencapai tahap diskriminasi 
yang maksimum di antara B. pseudomallei dengan spesies-spesies bakteria lain dan 
juga mempertingkatkan aras kebolehkesanannya. Ujian spesifisiti secara in-silico 
menunjukkan padanan tepat dengan rujukan gen sasaran, manakala spesifisiti 100% 
didapati apabila diuji terhadap B. pseudomallei dan bakteria lain termasuk B. 
thailandensis dan B. cepacia. 
 
Asai PCR ini juga menunjukkan sensitiviti 100% apabila diuji terhadap isolat-isolat 
dari genotip yang berlainan. Kepekatan DNA paling minimum yang dapat dikesan 
menggunakan asai sct-PCR ini ialah 100 fg/µl, manakala bilangan bakteria dalam 
darah yang paling sedikit yang berjaya dikesan ialah 18.2 X 10
5
 CFU/ml. Oleh itu, 
asai PCR yang dibangunkan dalam kajian ini mampu untuk mengesan secara spesifik 
bakteria yang disyaki B. pseudomallei dari plat kultur dan juga secara langsung dari 
spesimen klinikal. 
 
Kajian ini secara langsung telah memberikan satu ulasan meluas bagi penyakit 
melioidosis dan agen penyebabnya, B. pseudomallei dalam kalangan populasi yang 
menduduki bahagian timurlaut Semenanjung Malaysia. Ciri klinikal dan faktor risiko 
bagi penyakit ini tidak terhad kepada Malaysia sahaja dan genotip B. pseudomallei 
menunjukkan kepelbagaian yang berkait rapat dengan taburannya di persekitaran. 
Penemuan genotip baharu menggambarkan aktiviti serta ketakstabilan genetik 
bakteria ini yang boleh meramalkan kemunculan jenis-jenis bakteria baharu dengan 
kesan kevirulenan yang berbeza. Kajian ini juga menyokong kajian lepas yang 
mengandaikan bahawa faktor manusia dan persekitaran menjadi penyebab 
kepelbagaian gejala klinikal penyakit melioidosis ini. Bagi kaedah pengesanan secara 
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molekular, peningkatan dan penilaian yang lebih meluas diperlukan bagi 
mempertingkatkan prestasi asai ini. 
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CLINICAL CHARACTERISTICS, GENOTYPING AND 
MOLECULAR DETECTION OF 
Burkholderia pseudomallei 
 
ABSTRACT 
 
Burkholderia pseudomallei is a saprophytic Gram-negative bacterium that infects 
human body through inhalation, ingestion or percutaneous inoculation and causes 
melioidosis. The pathophysiology and clinical presentations of melioidosis are 
influenced by B. pseudomallei load on exposure, route of infection and human risk 
factors. Laboratory methods for B. pseudomallei include various procedures applied 
for diagnosis, molecular epidemiology and pathogenicity studies using conventional, 
immunological and molecular techniques.  
 
In this study, the clinical characteristics and risk factors of melioidosis were 
explored. Genotyping using multilocus sequence typing (MLST) was performed on 
clinical B. pseudomallei isolates to explore the degree of their genotypic diversity in 
the area of the study and to correlate the identified genotypes with clinical 
presentations and outcomes.  In order to improve the laboratory detection of B. 
pseudomallei, a PCR-based assay targeting sctq gene of the TTS1 cluster has been 
developed. 
 
In this study, which involved 158 cases, the principal clinical presentations reported 
were lung infection in 65 (41.1%), skin infection in 44 (27.8%), septic 
arthritis/osteomyelitis in 20 (12.7%) and liver infection in 19 (12.0%). Bacteremic 
melioidosis was seen in most cases (n=121, 76.6%). Focal melioidosis was seen in 
xxiv 
 
124 (78.5%) of patients and multi-focal melioidosis was reported in 45 (28.5%) 
cases, while melioidosis with no evident focus was reported in 34 (21.5%) patients. 
Internal organ abscesses and secondary foci in lungs and/or soft tissue were common 
in this study. Sixty seven (41%) patients were admitted during the monsoonal wet 
season. Death due to melioidosis was reported in 52 (32.9%) of patients, while 
recurrent infections occurred in 4 (2.5%) patients. Twelve fatal melioidosis cases 
directly attributed to the absence of prompt acute-phase treatment were seen in this 
study. Predisposing risk factors were reported in 133(84.2%) patients, which 
included diabetes (74.7%), immune disturbances (9.5%), cancer (4.4%) and chronic 
kidney disease (11.4%). On multivariate analysis, the independent predictors of 
mortality were the presence of at least one co-morbid factor (OR 3.0; 95% CI 1.1–
8.4), the occurrence of septic shock (OR 16.5; 95% CI 6.1–44.9) and age >40 years 
(OR 6.47; 95% CI 1.7–23.8).  
 
Multilocus sequence typing of 83 B. pseudomallei isolates has revealed 32 different 
sequence types, of which 13 (40%) were novel, namely: ST1317, ST1318, ST1319, 
ST1320, ST1321, ST1322, ST1323, ST1324, ST1325, ST1326, ST1327, ST1358 and 
ST1359. All retrieved sequence types were deposited in MLST database. The 
frequencies of sequence types among the 83 isolates ranged from 1-12 observations 
with predomination of ST54, ST371 and ST289. All non-novel sequence types 
identified in this study were not exclusive for Malaysia; they were identified in other 
regional countries with different frequencies. However, some of these sequence types 
were firstly identified in Malaysia such as ST371, ST164, ST47, ST306, ST55, 
ST376, ST402, ST507, ST368, ST369, ST10 and ST168.  
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Based on MLST data analysis, the constructed phylogenetic tree revealed more than 
half of the sequence types clustering with each other, as well as with the sequence 
types from Malaysia, Thailand, Singapore, Cambodia, Vietnam, Laos and China. 
Majority of novel sequence types were clustered with each other along the 
phylogenetic tree. The only novel and singleton sequence type in this study was 
ST1326. The present study has expanded the former Malaysian database for B. 
pseudomallei population genetics by adding more branching sequence types and the 
creation of new cluster after predicted clonal expansion emerged from ST84.  
 
There was no evidence of associations for B. pseudomallei sequence types with 
clinical melioidosis presentations on the evolution tree. No clustering of particular 
sequence types with a given clinical outcome was noted. In addition, there was no 
evidence of differential virulence or strain tropism. Severe sepsis (n=11) was caused 
by strains of 7 different sequence types, while both septic shock (n=29) and 
abscesses (n=30) were caused by strains of 17 and 18 different sequence types, 
respectively. Presentations with sepsis, pneumonia, different melioidosis types, 
septic encephalopathy and other organ infections and disease outcome were caused 
by strains of several different sequence types. Finally, two-way tables for all 
bacterial genotype clusters in relation with each clinical outcome were statistically 
insignificant and no risk estimate was reported for every genotype cluster for 
developing any of clinical outcomes.  
 
PCR was optimized to achieve the maximal discrimination between B. pseudomallei 
and its genetic relatives and to enhance the best detection limit. The in-silico 
specificity test showed complete match with a reference sequence for the target gene. 
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sctQ-PCR showed 100% specificity once tested against B. thailandensis and B. 
cepacia and a panel of genetically related and non-related microorganisms DNA. 
The sensitivity was 100% after successful amplification of isolates of different 
MLST strains and genotypes. The lower concentration of purified B. pseudomallei 
DNA that was amplified by sctQ-PCR was 100 fg/µl, whereas the lowest number of 
bacterial cells detected in spiked blood specimens was 18.2 X 10
5
 CFU/ml.  The 
developed PCR assay was capable of specific identification of suspected B. 
pseudomallei from cultured plate or directly from clinical specimens. 
 
This study has provided major review for melioidosis and its causative agent, 
Burkholderia pseudomallei among selected population clusters residing in the 
Northeastern part of Peninsular Malaysia. Clinical presentations and risk factors of 
melioidosis were not unique for Malaysia and B. pseudomallei genotypes showed 
wide diversity that was correlated with the distribution of different strains in the 
environment. Novel sequence types indicated the genetic activity and instability of 
the bacteria which predicted the emergence of new strains that may harbor different 
virulence effect. This work kept on previous assumption that host and environmental 
factors were behind the diversity for clinical presentation of the disease. For 
molecular diagnosis, further upgrading and evaluation are needed to improve the 
performance of the assay. 
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                           CHAPTER ONE
INTRODUCTION & LITERATURE REVIEW 
 
1.1. History of Nomenclature  
 
The early history of Burkholderia pseudomallei discovery was started in 1911 when a 
pathologist Alfred Whitmore and his assistant Krishnaswami noticed unusual 
bacterial infection presentation in multiple organs during the postmortem examination 
of a Burmese man with pneumonia and described the case in the literature in 1912.  
 
Subsequently, both authors described cases of fatal septicemic disease with multiple 
organs abscesses in 38 patients that were clinically similar to glanders disease in 
animal, which was identified in 1885, and the clinical condition was named 
Whitmore’s disease.  
 
In all cases, Gram negative bacilli were grown on peptone agar and potato slopes and 
were differentiated from glanders agent (Pseudomonas mallei) by rapid growth, 
motility, colony appearance on agar and lack of Strauss reaction in guinea pigs.  
 
These characteristics were sufficiently distinctive to recognize the isolated bacilli as 
new species; Bacillus pseudomallei which was closely related to P. mallei. Since 
1913, doctors Stanton and Fletcher had recognized the same disease in laboratory 
animals and humans and reported many cases as the first discovery of the disease in 
Malaysia.  
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Because the disease was clinically and pathophysiologically similar to glanders, the 
same doctors proposed the name melioidosis (melis: distemper of asses; oid: like; 
osis: a condition) which refers to glanders-like infection.  
 
Melioidosis agent was known by several names over decades, including Bacillus 
whitmori, Pfeifferella whitmori, Pfeifferella pseudomallei, Actinobacillus 
pseudomallei, Flavobacterium pseudomallei, Loefflerella whitmori, Loefflerella 
pseudomallei, Bacillus pseudomallei, Malleomyces pseudomallei and Pseudomonas 
pseudomallei (Puthucheary, 2009; Currie, 2015a). 
 
In 1992, with the molecular revolution of bacterial classification, Yabuuchi and co-
workers proposed a new genus Burkholderia (named after Walter Burkholder who 
first described Burkholderia cepacia) based on the 16S rRNA sequences, DNA-DNA 
homology, composition of cellular lipid and fatty acid, and phenotypic characteristics.  
 
The species pseudomallei, along with six species under this group, were transferred to 
the new genus and became Burkholderia pseudomallei, Burkholderia mallei, 
Burkholderia solanacearum, Burkholderia gladioli, Burkholderia caryophylli, 
Burkholderia pickettii and Burkholderia cepacia (Yabuuchi and Arakawa, 1993).  
 
These findings, and in addition to the continuous speciation of other Pseudomonads 
under the genus Burkholderia were confirmed by recent molecular genotyping studies 
(Rainbow et al., 2002; Godoy et al., 2003).   
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Burkholderia genus belongs to the class Beta-Proteobacteria, order Burkholderiales 
and family Burkholderiaceae, and encloses more than 30 species that are mostly 
nonpathogenic soil-dwelling bacteria such as B. thailandensis which is genetically 
closed to few pathogenic species, such as B. cepacia, B. mallei and B. pseudomallei 
(Currie, 2015a). 
 
Burkholderia pseudomallei is a small gram-negative, nonsporulating, straight or 
slightly curved bacillus, oxidase-positive, motile and aerobic. It exhibits bipolar 
staining (safety-pin appearance) due to accumulation of poly-β-hydroxybutyrate.  
 
Bacterial cells are approximately 0.4-0.6 µm in width and 2-5 µm in length with two 
to four polar flagella. The bacterium is easily recovered on routine culture media and 
produces variable colony morphologies in appearance.  
 
Previously, B. pseudomallei was classified by the Centers for Disease Control and 
Prevention (CDC) as category-B biothreat (Dance, 2008). However, B. pseudomallei 
was upgraded to Tier 1 Biological Select Agent status as a biothreat beside Bacillus 
anthracis and Yersinia pestis.  
 
This ranking system is reserved for infectious agents that have the greatest risk to 
human and animal health and was declared by the U.S. Department of Health and 
Human Services (HHS) and known as Biological Select Agents or Toxins" (BSATs) 
(Butler, 2012). 
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B. pseudomallei K96243 genome contains two chromosomes: chromosome 1 (4.07 
Mb) is composed of housekeeping genes involved with metabolism, motility and 
biosynthesis of cellular components. Chromosome 2 (3.17 Mb) genes are thought to 
be involved with adaptation within the environment and host.  
 
The genome of B. pseudomallei is of great plasticity that leads to genetic divergence 
due to frequent mutations, gene transfer and recombination that influence strain to 
strain variation (Holden et al., 2004).  
 
Recently, many studies reported wide genetic diversity of B. pseudomallei  (De Smet 
et al., 2015; Nandi et al., 2015), as well as cases of genetic divergence reported 
among isolates within the same melioidosis patient and indicated within-host 
adaptation (Price et al., 2010; Limmathurotsakul et al., 2014a).  
 
In addition, morphological changes in B. pseudomallei colonies for a single strain was 
also observed and reported in strains isolated from various specimens types from 
melioidosis patients and has been associated with bacterial adaptation to adverse 
conditions (Chantratita et al., 2007a; Tandhavanant et al., 2010). 
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1.2. B. pseudomallei in the Environment and Associated Risk Factors 
 
Burkholderia pseudomallei is a saprophytic organism which is able to survive for 
extended periods of time in variety of harsh environmental conditions like nutrient 
deficiency, different temperatures and pH and wide range of physical, chemical and 
biological factors (Cheng and Currie, 2005) and is capable of infecting the free-living 
protozoa Acanthamoeba astronyxis (Inglis et al., 2000b). However, B. pseudomallei 
exclusively inhabits the environment in tropical regions of the world located between 
20N and 20S lines of latitude and can be recovered from water and wet soils, 
particularly rice paddies (Cheng and Currie, 2005).  
 
Many studies tested environmental samples to investigate for B. pseudomallei and 
understand its geographical distribution in Thailand (Wuthiekanun et al., 2009), 
Northern Australia (Cheng et al., 2008a), Taiwan (Chen et al., 2010), Papua New 
Guinea (Warner et al., 2008) PDR Lao (Wuthiekanun et al., 2005c), Malaysia 
(Ellison et al., 1969; Strauss et al., 1969b) and Brazil (Rolim et al., 2009) and found 
that B. pseudomallei was more common in rice paddies and farms (Wuthiekanun et 
al., 1995; Kaestli et al., 2009).  
 
A study concluded that the increased incidence of melioidosis in an area, might be 
partly correlated with the increased bacterial density in the environment of that area 
and also found that the increased exposure to bacteria was resulted from changes in 
behaviors of farmers and work style; such as farming techniques (Chantratita et al., 
2008b). In Australia, B. pseudomallei was found most commonly in wet soils to a 
depth of 25 to 45 cm with the proposal of moving to the surface with rising water 
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table during the monsoon events that increases the surface bacterial load and then 
increasing the infective dose that enhance the chance for severe acute infection 
(Grivas et al., 2015). However, studies from Malaysia showed less correlation of 
melioidosis with rainfall and reported no significant association between month of 
patients’ admission to hospital and mortality due to melioidosis (Sam and 
Puthucheary, 2007; Deris et al., 2010). 
 
1.3. Modes of Acquisition  
 
Three common modes of B. pseudomallei entry were recognized in human and 
animals: inhalation of aerosolized bacteria, ingestion of contaminated food and water 
and percutaneous inoculation (Currie, 2015b). Inhalation of contaminated dust was 
initially thought to be the primary route of transmission of B. pseudomallei according 
to the earlier cases of respiratory melioidosis in soldiers exposed to dust in Vietnam 
(Howe et al., 1971). Recent report was documented in Singapore for a case of 
inhalation-associated melioidosis in a returning tourist (Amadasi et al., 2015). Animal 
studies also demonstrated the potential importance of aerosol inhalation model and 
reported high lethality observations (Nelson et al., 2011; West et al., 2012b). 
However, the overall incidences of inhalation melioidosis remain uncertain in 
comparing with other routes (Currie, 2015b). B. pseudomallei gain access through the 
direct contact of contaminated soil and water with percutaneous wounds or existing 
skin abrasions, ulcers, or burns (McLeod et al., 2015). During massive weather events 
such as monsoonal storms, typhoons and tsunami, the route of bacterial entry might 
be shifted from inoculation to inhalation as the predominant route of transmission 
(Chen et al., 2014).  
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In spite of conclusions made for the impossibility of the ingestion route for 
transmission (White, 2003; Dance, 2008), few reports described disease acquisition 
via ingestion of contaminated food or drink (Ketterer et al., 1986; Currie et al., 2001). 
However, rivers in tropical environments and unchlorinated domestic water supplies 
that may comprise high bacterial load expect to uncover for higher risk of ingestion 
melioidosis than previously thought. This was supported by previous literatures 
findings of melioidosis outbreaks reported in Thailand that were linked to 
contamination of potable unchlorinated water with B. pseudomallei 
(Limmathurotsakul et al., 2014b; Thaipadungpanit et al., 2014). 
 
Less common melioidosis transmission routes have been reported including mother to 
child (Ralph et al., 2004), sexual transmission (Thatrimontrichai and Maneenil, 2012), 
laboratory acquired (Schlech et al., 1981), animals to humans (Choy et al., 2000) and 
person-to-person transmission (Holland et al., 2002). 
 
1.4. Melioidosis: Pathology and Pathogenesis  
 
Melioidosis has emerged over the past 20 years as an important cause of morbidity, 
mortality, and fatal community-acquired bacteremic pneumonia. Melioidosis 
pathophysiology and clinical presentations, degree of disease severity and outcomes 
are all influenced by B. pseudomallei load on exposure (infecting dose) that might be 
controlled by environmental risk factors; route of infection acquisition (inhalation, 
percutaneous inoculation or ingestion); virulence factors of the infecting B. 
pseudomallei strain and most importantly the host risk factors (Currie, 2015a). 
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1.4.1. Virulence Factors 
 
Burkholderia pseudomallei is an intracellular pathogen which multiplies inside 
phagocytic and nonphagocytic cells and possesses many genes responsible for 
metabolism pathways and surface components synthesis such as lipopolysaccharide 
and capsular polysaccharide. The structural and functional aspects of B. pseudomallei 
components, their regulation, and their role in pathogenesis as virulence factors are 
still incompletely or poorly understood. Examples of B. pseudomallei virulence genes 
include those encoding for proteases, lipases, lecithinase, catalase, perioxidase, 
hemolysins, cytotoxins, adhesions, invasins, fimbriae and pili, and secretion systems 
types II, III and VI (Sarovich et al., 2014a) (table 1.1).  
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(Cheng and Currie, 2005; Lazar Adler et al., 2009; Galyov et al., 2010) 
 
 
Table 1.1: Examples for virulence factors of B. pseudomallei and their relative 
importance in melioidosis pathogenesis  
 
Virulence factor Description Role during pathogenesis 
Capsule 200-kD capsular 
polysaccharide composed 
of a homopolymer of-3)-2-
O-acetyl- 6-deoxy-β- D-
manno-heptopyranose 
Required for epithelial 
attachment and survival and/or 
replication in macrophages and 
during bacteremia by reducing 
C3b-mediated opsonization and 
phagocytosis  
Lipopolysaccharides Unbranched 
heteropolymer made of D-
glucose and L-talose units 
with the structure -3)-β- 
D-glucopyranose-(1–3)-6-
deoxy-α- L-talopyranose. 
Confers resistance against 
macrophage killing and 
promotes survival during 
bacteremia by preventing killing 
by the alternative pathway of 
complement 
Flagellin Surface-associated 43-kDa 
protein 
Required for motility and 
optimal invasion of non-
phagocytic cells 
Fimbriae and pili-IV Same structure of flagella  Bacterial attachment to  
epithelial surfaces and 
microcolony formation 
Quorum sensing Seven quorum-sensing 
molecules, including C8-
HSL, 3-hydroxy-C8-HSL, 
3-oxo-C8-HSL, C10-HSL, 
3-hydroxy-C10-HSL, 3-
oxo-C10-HSL, 3-hydroxy-
C12-HSL, and 3-oxo-C14-
HSL 
Coordinate biofilm 
synthesis, virulence, 
and antibiotic resistance based 
on the local density of the 
bacterial population. 
Secretion systems 
genes 
Cluster of genes located in 
pathogenicity island gene 
cluster 
Type II secretion system 
(T2SS): secretion of protease, 
lipase, and phospholipase C 
Type III secretion system 
(T3SS): inject host cells with 
bacterial toxin and so called 
toxin gun 
Type VI secretion system 
(T6SS): modulate intracellular 
persistence  
Exoproteins Phospholipase C (PLC):  
77-kDa proteins putative 
nonhemolytic enzyme 
Metalloprotease: a 47-kDa 
protease 
PLC:  hydrolyse lipids, 
phosphatidylcholine and 
sphingomyelin 
Metalloprotease:  have cytotoxic 
and proteolytic activities 
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In vivo infection models, immunological, cellular and molecular studies were done to 
understand the impact of each virulence element of the bacteria. The study of lethal 
effect for a given structural virulence factor is usually performed by preparing 
genetically-modified B. pseudomallei mutants for certain virulence factor and then 
used to infect a laboratory animal (Currie, 2015a). Another principle is to inject a 
laboratory animal with purified B. pseudomallei-antigen that represents certain 
structural virulence factor and demonstrate degree of induced passive protection 
(Currie, 2015a). Several studies were performed on passive immunity using capsule-
mutants (Atkins et al., 2002a), lipopolysaccharides-mutants (Jones et al., 2002) and 
flagillin-mutants (Chua et al., 2003) showed low virulence of these mutants and 
reported positive protection effect of the anti-sera of all antigens against lethal 
bacterial challenge. Genetically muted B. pseudomallei for enzymes, secretory and 
signaling systems were also studied, including quorum sensing (Ulrich et al., 2004), 
secretion systems type II, III and VI (Warawa and Woods, 2005; Pilatz et al., 2006) 
and proteases (Boddey et al., 2007).  
 
1.4.2. Bacterial Attachment and Cell Invasion   
 
Burkholderia pseudomallei is transmitted from its environmental reservoir to human 
host and attached to epithelial cell layers of either the abraded skin, the mucosal 
surface of the lungs or gastrointestinal tracts where it initially attaches by the capsule 
and type 4 pili. Once the epithelial attachment is maximized, bacteria start forming 
pili-mediated microcolonies (Galyov et al., 2010).  
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Type III secretion system effectors assist bacterial invasion by saving the engulfed 
bacteria from autophagy killing via promoting the disruption of phagosomal 
membranes and facilitate the escape of bacteria into the host cytosol. Now the free 
bacterial cells in the cytosol start replication by the promotion from Type VI 
secretion system effectors. Once bacterial quorum sensing system alert for critical 
density threshold level for B. pseudomallei build up within host cell, B. pseudomallei 
induce apoptosis to lyse the host cell in order to escape and invade another cell 
(Lazar Adler et al., 2009) (figure 1.1). As the invasion progresses, B. pseudomallei 
spread to body organs via the lymphatic vessels, either carried within macrophages 
or as free bacteria in the circulation with protection against circulating antibodies 
mediated by capsule and lipopolysaccharides (Lazar Adler et al., 2009).  
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Figure 1.1: Demonstration of infection events beginning with cellular attachment and evading auto-phagosomes then invading adjacent cell. PM: 
plasma membrane, PRR: pathogen recognition receptor. Adapted from Galyov et al., (2010).  
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1.4.3. Host Immune Response   
 
Burkholderia pseudomallei induces humoral and cell-mediated responses during 
disease stages. Individuals who were exposed to B. pseudomallei develop IgA, IgM, 
and IgG antibodies that are increased during acute infection and their levels correlate 
with the severity of the disease. During severe melioidosis, the levels of pro-
inflammatory cytokines and immunoregulatory cytokines indicate an extensive 
activation of the cellular immune response. In addition, the cellular immunity plays a 
key role in controlling the infection in asymptomatic seropositive individuals 
(Sarkar-Tyson et al., 2009) (figure 1.2).  
 
After melioidosis recovery, high levels of antibodies remain elevated for years in 
patient’s serum, suggesting continuous exposure to B. pseudomallei or sequestration 
of bacteria in intracellular sites of latency (Gan, 2005). In spite of the role of cell-
mediated immune response in the neutralizing and protection against disease 
progression, there is no definitive evidence for the protective immunity against 
melioidosis which allow reinfection occurrence with a different B. pseudomallei 
strain after successful treatment (Currie, 2015b). 
 
Several studies showed the association of elevated levels of various inflammatory 
mediators with the severity of melioidosis. Nuntayanuwat et al., (1999) found an 
association between severe melioidosis and TNF-α gene allele 2 which was 
represented by higher production of TNF-α.  
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In a study, mouse model was used for melioidosis and showed that TNF-α or IL-12 
neutralization has increased mice susceptibility to infection; in that study treated 
mice with monoclonal anti–IFN-γ antibodies died more quickly which indicated the 
importance of IFN- γ for protection (Santanirand et al., 1999). Toll-like receptors 
(TLR) role has been proposed and confirmed in the innate immune response in 
melioidosis (West et al., 2012a). 
 
Evasion mechanisms were recognized to enable B. pseudomallei to escape from host 
immune response by decreasing immune response stimulation through expression of 
unusual lipopolysaccharide structures (Utaisincharoen et al., 2000), intracellular 
spreading by actin polymerization (Breitbach et al., 2003), complement inhibition by 
bacterial capsule (Reckseidler-Zenteno et al., 2005), escaping from endosome to 
cytosol (Stevens et al., 2002), induction of macrophage apoptosis (Sun et al., 2005) 
and inhibition of cytokines release (Utaisincharoen et al., 2001).   
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Figure 1.2: Cellular infection, spread and host immune response. Adapted from Lazar Adler et al., (2009) 
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1.4.4. Clinical Manifestations  
 
Melioidosis is a multi-system infection with non-specific signs and symptoms. The 
clinical spectrum of melioidosis is broad, therefore, several clinical classifications 
were proposed and identified the infection as bacteremic versus nonbacteremic, 
multifocal versus localized, and acute versus chronic melioidosis (Currie, 2015a).   
 
Melioidosis cases were categorized according to The Infectious Disease Association 
of Thailand as: bacteremic multifocal infection with septicemia; bacteremic localized 
infection with septicemia; non-bacteremic localized infection and melioidosis with 
transient septicemia (Leelarasamee and Bovornkitti, 1989).  
 
B. pseudomallei strains differ in their ability to cause disease and the outcome 
depends on the immune status and response of the infected host. Melioidosis 
incubation period is influenced by the mode of infection, inoculation dose, host risk 
factors, and strain virulence. The incubation period of melioidosis starts from the 
event of infection and extends until the onset of symptoms appearance but still has 
not been accurately estimated. An incubation period of 1-21 days (mean 9 days) was 
suggested to precede acute melioidosis, which is consistent with a series of 
nosocomial cases from Thailand (Puthucheary, 2009). Chronic melioidosis is defined 
as illness with symptoms duration of more than 2 months (Currie et al., 2000). 
 
In inhalation melioidosis, the infection is primarily localized and started from the 
lungs and could be asymptomatic or subclinical and the bacteria may colonize the 
lungs for latent stay. On the other hand, the infection could be aggressive and is 
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characterized by severe pneumonia and bronchitis leading to chest pain and shortness 
of breath and may spread to pleural fluid (Currie, 2015a). An evidence-based 
definition for inhalation melioidosis was recently described (Cheng et al., 2013). In 
case of infection dissemination from the lungs, B. pseudomallei can enter blood 
stream and disseminates to other organs where the pathogen may colonize and cause 
deep seated abscesses (Cheng et al., 2013) (figure 1.3). 
 
Upon percutaneous inoculation, localized inflammatory process started with the 
production of large amounts of pus exudate consisting of neutrophils and edema fluid 
that leads to local suppuration accompanied by fever, rigors, and malaise. 
Suppurating abscess in the skin layers may involve the deeper tissues of muscles and 
bone which is common in untreated cases. In general, for inoculation melioidosis, the 
infection started with skin abscess followed by bacteremia and secondary organ 
abscesses (Currie, 2015b).   
 
Acute melioidosis is more associated with the environmental and individual risk 
factors, whereas reactivated latent infections are associated with individual risk 
factors (Pitt et al., 2007; Lazar Adler et al., 2009).   
 
The mortality of acute melioidosis is 30-47% (Peacock et al., 2011); untreated 
bacteremic melioidosis increases the mortality rates to 80-90% within two days of 
hospital admission (Lowe et al., 2013). In endemic areas, melioidosis had mortality 
rate at 9%, in Australia (Currie et al., 2010) and 34% in Malaysia (Hassan et al., 
2010). Pneumonia and sepsis are the most severe clinical manifestations of 
melioidosis (White, 2003). In addition, pneumonia is the most common presentation 
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of melioidosis (Cheng and Currie, 2005). In Thailand, melioidosis cause 20% of 
community-acquired septicemia which accounts for 39% of fatal septicemia cases 
(Chaowagul et al., 1989) and 36% of fatal community-acquired pneumonia (Boonma 
et al., 1990). In addition, melioidosis was responsible for most cases of fatal 
community-acquired septicemic pneumonia in tropical Australia (Currie et al., 
2010). 
 
The recurrent infection is defined as a new presentation of acute culture-confirmed 
melioidosis after recovery from previous infection upon completion of antibiotic 
therapy regime. Recurrent infection occurs in 6–13% of melioidosis cases due to 
relapse of the infection by the same bacterial strain rather than reinfection with a new 
bacterial strain (Currie et al., 2000; Maharjan et al., 2005). In Thailand, the overall 
relapse rate was up to 30% per year of survivors who had severe melioidosis 
(Chaowagul et al., 1993). While in Malaysia, the rate of relapse or recurrence was 
approximately 13% over a period of 5 years (Puthucheary, 2009). In Australia, 
Sarovich et al.,( 2014b) had reported improved recurrent melioidosis rate in Darwin 
hospital over 23 years and documented recurrent infection in 39/679 (5.7%); in 
which 29 patients suffered relapsed infection, while the rest got re-infected with new 
B. pseudomallei.  
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Figure 1.3: Clinical involvement of melioidosis from the starting point of entry. 
Adapted from Currie (2015a). 
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1.4.5. Human Risk Factors  
 
Many of melioidosis cases occur in individuals with pre-existing illnesses; up to 80% 
of melioidosis patients have one or more risk factors, whereas risk factors are less 
common in children (Currie, 2015b). In Australia, a prospective melioidosis study 
over 25 years reported that 113 of the 115 death cases were directly attributed to one 
or more known risk factors (Currie et al., 2010). In the same country, a 24-year 
prospective study was done recently to review the clinical presentations and 
outcomes of pediatric melioidosis. Out of 820 patients, 45 pediatric cases were 
identified, representing 5% of melioidosis. About 84% of children had no recognized 
risk factors for melioidosis (McLeod et al., 2015). In Malaysia, the percentage range 
of patients at risk was 77-90% (How et al., 2005; Deris et al., 2010; Hassan et al., 
2010).  
 
The recognised risk factors in melioidosis patients were type II diabetes mellitus, 
chronic renal failure, dengue hemorrhagic fever, immunosuppressive treatments, in 
particular steroids, α-thalassemia, chronic liver and lung disease and neutropenia 
(Dance, 2008). There is no evidence that human immunodeficiency virus infection 
predisposes to melioidosis (Cheng and Currie, 2005). However, the association of 
melioidosis with diabetes is strong and may increase the risk of the infection by up to 
100-fold (Suputtamongkol et al., 1994). Pre-existing or newly diagnosed type-2 
diabetes mellitus is the most frequently reported predisposing factor for melioidosis 
(Puthucheary, 2009). In Malaysia about 70-89% of melioidosis patients had diabetes 
(How et al., 2005; Deris et al., 2010; Hassan et al., 2010), 37% in Australia (Currie 
et al., 2010) and 53-60% in Thailand (Suputtamongkol et al., 1999). 
21 
 
Melioidosis affects all age groups. In Malaysia, it was found that the peak age-
specific incidence of melioidosis occur from 41–59 years for both males and females 
(Puthucheary, 2009), but in Thailand it was 60-69 years for men and 50-59 years for 
women (Suputtamongkol et al., 1994). Males are at higher risk of gaining the 
infection than females; probably because of differences in exposure to bacterial 
reservoir such as soil during rice farming. The male-female ratio for melioidosis was 
higher in all studies in Malaysia (Hassan et al., 2010), Australia (Currie et al., 2010), 
Thailand (Limmathurotsakul et al., 2010b),and Singapore (Lo et al., 2009). 
However, rapid diagnosis, appropriate antibiotics, and proper sepsis management 
will reduce the rate of death in melioidosis patients with predisposed risks and death 
is extremely uncommon in those without identified risk factors for melioidosis (Deris 
et al., 2010). 
 
1.5. Epidemiology of Melioidosis  
 
Melioidosis occurs predominantly in Southeast Asia, northern Australia, the Indian 
subcontinent and China (figure 1.4). Cases were first described in Burma 1912, 
Malaysia 1913, Singapore 1913, Vietnam 1925 and Indonesia 1929 (Leelarasamee, 
2000). Although Thailand and Australia have the highest endemicity of melioidosis, 
it was not documented in Thailand until 1955 and in Australia until 1949. In 
Thailand, the annual melioidosis incidence rate was 4.4 per 100,000 
(Suputtamongkol et al., 1994) with frequently documented cases from the 
northeastern provinces (Limmathurotsakul et al., 2010b).  
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Figure 1.4: Worldwide distribution of melioidosis. Adapted from Currie, 2015a. 
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The epidemiological studies have defined an annual incidence rate of 16.5 per 
100,000 and reported 540 melioidosis cases over 20 years in tropical Australia 
(Currie et al., 2010). In Northeastern Malaysia, 35 melioidosis cases were reported 
over 5 years (Deris et al., 2010) and the annual incidence rate was 6.1 per 100,000 
population in central state of Malaysia (How et al., 2005).  
 
The history of melioidosis in Malaysia began with description of infection in animal 
by Stanton and Fletcher as far back as 1913, and then human cases were 
subsequently published in 1932. Strauss et al., (1969a) has conducted a sero-survey 
using indirect haemagglutination assay in 1964 to 1966, and reported 7.3% 
seropositivity. In Malaysia the sero-prevalence of melioidosis using different 
serological procedures and was 7% (Vadivelu et al., 1995). More recent Deris et al., 
(2010) described the clinical characteristics and outcomes of 35 melioidosis 
identified in Kelantan state over 5 years. In Pahang state, 63 confirmed cases of 
melioidosis were identified over a year and the annual incidence rate of melioidosis 
was calculated as 6.1 per 100,000 of population (How et al., 2005). In Kedah state, 
the incidence of melioidosis was 16.35 per 100,000 populations per year, which was 
remarkably much higher than the rates recorded in other Southeast Asian countries 
(Hassan et al., 2010). 
 
Melioidosis is now well recognized in epidemiology studies and case series 
documented from Singapore (Lo et al., 2009), Brunei (Pande and Kadir, 2011), Laos 
(Phetsouvanh et al., 2001), Vietnam (Parry et al., 1999), China (Yang, 2000), 
Taiwan (Chen et al., 2004), Myanmar (Wuthiekanun et al., 2006c), Cambodia 
(Wuthiekanun et al., 2008) India (Dance et al., 1995), and Sri Lanka (Corea et al., 
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2012). Although melioidosis is highly endemic in parts of Southeast Asia, cases were 
rarely reported in Indonesia; Tauran et al., (2015) reported three cases of fatal 
melioidosis occurred between 2013 and 2014 beside seven cases reviewed from old 
literature. It was assumed that melioidosis could be endemic but still under-
recognized throughout Indonesia and recommended that considerations should be 
given to make melioidosis a notifiable disease in Indonesia. 
  
Cases of melioidosis from outside the classic endemic regions were increasingly 
being documented. This includes sporadic cases for human or animal infections or 
environmental isolates from the Middle East, Europe, Africa, the Caribbean, Brazil 
and in the Americas (Inglis et al.,2006; Salam et al., 2011; Borgherini et al., 2015; 
Wiersinga et al., 2015). 
 
1.6. B. pseudomallei Laboratory Methods  
 
Laboratory methods for B. pseudomallei include conventional, molecular and 
immunological procedures that are applied for infection diagnosis, molecular 
epidemiology and pathogenicity studies (Hoffmaster et al., 2015).  
 
1.6.1. Laboratory Diagnosis  
The highly variable presentations of melioidosis make the clinical diagnosis 
impossible without the aid of confirmatory laboratory testing. Melioidosis should be 
suspected in cases of febrile illnesses presenting with respiratory failure, multiple 
subcutaneous lesions, or tuberculosis-like radiological pattern (Puthucheary, 2009).  
 
